Merayo-Lloves Jesús, Sanchez Ronald M, Riestra Ana C, Anitua Eduardo, Begoña Leire, Orive Gorka, Fernandez-Vega Luis
Instituto Universitario Fernx00E1;ndez-Vega, Fundacix00F3;n de Investigacix00F3;n Oftalmolx00F3;gica, Universidad de Oviedo, Oviedo, Spain.
Ophthalmic Res. 2015;55(2):53-61. doi: 10.1159/000439280. Epub 2015 Nov 17.
Preliminary information about the safety and efficacy of plasma rich in growth factors (PRGF) eyedrops in the treatment of refractory cases of diverse ocular surface disorders (OSDs) is presented here.
This retrospective cohort study included cases with OSDs refractory to previous treatment with conventional treatments or autologous serum or cyclosporine, and treated with PRGF eyedrops. The signs and symptoms of ocular surface disorders [using the ocular surface disease index (OSDI), best-corrected visual acuity (BCVA), visual analog scale (VAS) frequency and VAS severity] were evaluated before and after treatment with PRGF. A safety assessment was also performed reporting all adverse events or complications.
Forty-one patients with a total of 80 treated eyes were evaluated. Statistically significant reductions in the OSDI scale (39.27%), VAS frequency (38.9%) and VAS severity (40.3%), and a significant improvement in BCVA (54.86%) were all observed (p < 0.05). The results were stratified according to the identified potential effect modifiers. There were only two adverse events (eye redness and eyelid inflammation), which were reported as mild and resolved in a few days.
PRGF eyedrops could be a safe and effective treatment option for refractory cases of OSDs. When treating patients the possible influence on the results of some clinical variables must be taken into account.
本文介绍了富含生长因子的血浆（PRGF）滴眼液治疗多种眼表疾病（OSD）难治性病例的安全性和有效性的初步信息。
这项回顾性队列研究纳入了经传统治疗、自体血清或环孢素先前治疗无效，而接受PRGF滴眼液治疗的OSD病例。在用PRGF治疗前后，评估眼表疾病的体征和症状[使用眼表疾病指数（OSDI）、最佳矫正视力（BCVA）、视觉模拟量表（VAS）频率和VAS严重程度]。还进行了安全性评估，报告所有不良事件或并发症。
共评估了41例患者的80只治疗眼。观察到OSDI量表（39.27%）、VAS频率（38.9%）和VAS严重程度（40.3%）有统计学意义的降低，BCVA有显著改善（54.86%）（p<0.05）。根据确定的潜在效应修饰因素对结果进行分层。仅报告了两例不良事件（眼红和眼睑炎症），均为轻度，数天内缓解。
PRGF滴眼液可能是OSD难治性病例的一种安全有效的治疗选择。在治疗患者时，必须考虑对某些临床变量结果的可能影响。
